Immuneering (IMRX) Preferred Stock Liabilities (2020 - 2021)
Immuneering (IMRX) posted quarterly Preferred Stock Liabilities of $82.9 million for Q2 2021, up 292.49% year-over-year from $21.1 million in Q2 2020, and up 124.13% quarter-over-quarter from $37.0 million in Q1 2021.
Immuneering (IMRX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Immuneering's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $82.9 million for Q2 2021.
- In Q2 2021, Preferred Stock Liabilities rose 292.49% year-over-year to $82.9 million; the TTM figure through Jun 2021 stood at $82.9 million (up 292.49% YoY), while the FY2020 annual figure was $21.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2021 stood at $82.9 million, up from $37.0 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $82.9 million in Q2 2021, with the low at $21.1 million in Q2 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Immuneering | 327.37 Mn | 327.37 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 82.89 Mn |
| Mar 31, 2021 | 36.98 Mn |
| Dec 31, 2020 | 21.12 Mn |
| Sep 30, 2020 | 21.12 Mn |
| Jun 30, 2020 | 21.12 Mn |